Latest Conference Coverage

Open Label Extension Data Shows Lecanemab’s Continued Effect on Alzheimer Disease After 3 Years

The 3-year data highlighted the safety profile of lecanemab and its disease-modifying effects on tau accumulation and other biomarkers related to AD pathology.

Highly Accurate Blood Test Enhances Alzheimer Diagnosis in Primary and Secondary Care

The use of a blood test significantly improved diagnostic accuracy compared with standard clinical evaluations for Alzheimer disease, especially in primary and secondary care settings.

Recent Advancements in Alzheimer Disease Research Presented at AAIC 2024: Rebecca M. Edelmayer, PhD

The vice president of scientific engagement at Alzheimer's Association talked about recent studies that highlight the progress made in blood biomarker tests for diagnosis, the impact of air pollution on brain health, and promising treatments for Alzheimer disease. [WATCH TIME: 8 minutes]

GLP-1 Agonist Liraglutide Shows Protective Effects on Alzheimer Disease in Phase 2 Trial

Although the primary endpoint of cerebral glucose metabolic rate change was not met, secondary endpoints showed significant benefits in brain volume and cognitive measures, further supporting the potential of GLP-1 agonists in AD.

AAIC Data Highlights Therapeutic Potential of CT1812 in Alzheimer Disease

CT1812, a sigma-2 receptor ligand, showed favorable changes in biomarkers like Aß40, Aß42, and neurofilament light (NfL), indicating its potential as a synaptoprotective agent.

Higher MIND Diet Scores Associated With Larger Brain MRI Hippocampal Volume

Higher MIND diet scores correlate with larger hippocampal volume in older adults, suggesting potential benefits for brain health.

Processed Red Meat Intake Linked to Increased Dementia Risk and Cognitive Decline

A study recently presented at AAIC 2024 showed that higher consumption of processed red meat significantly increased the risk of dementia and cognitive decline among adults in the United States.

NeuroVoices: Soeren Mattke, MD, DSc, on Utilizing Blood Tests to Reduce Wait Times and Improve Diagnosis in Alzheimer Disease

The director of the Brain Health Observatory at the University of Southern California discussed the potential impact of Alzheimer disease blood tests on reducing clinic wait times and improving the diagnostic process in primary care.

CoMPoSER, Developing a Music-Based Sleep App for Patients With Dementia and Caregivers: Darina Petrovsky, PhD, RN

The assistant professor at Duke University School of Nursing talked about a project aimed at developing a music-based mobile app to improve sleep for individuals with dementia and their caregivers. [WATCH TIME: 5 minutes]

Understanding the Therapeutic Potential of Lomecel-B for Alzheimer Disease: Joshua Hare, MD

The co-founder and chief science officer at Longeveron provided commentary on the therapeutic potential of Lomecel-B, a living cell product in development for patients with Alzheimer disease. [WATCH TIME: 3 minutes]

Y-Secretase Modulator RG6289 Produces Dose-Dependent Shift of Amyloid-ß Monomers in Phase 1 Study

A small clinical trial showed RG6289 dose-dependently altered amyloid-ß monomers in CSF, supporting its development for Alzheimer's disease.

Potential Cognitive Benefits of Using GLP-1 Analogs for Alzheimer Disease Treatment: Paul Edison, MD, PhD

The professor of neuroscience at Imperial College London talked about results from a study assessing a glucagon-like peptide-1 analogue, liraglutide, in patients with Alzheimer disease. [WATCH TIME: 5 minutes]

Education and Number of Household Members Negatively Impacts Cognitive Outcomes in Latino Individuals

In Latino individuals, larger household size negatively affects MoCA scores, while higher education positively impacts cognitive outcomes, per SERVE OC trial data.

Expanding the Knowledge Profile and Treatment Capabilities of Lecanemab: Lynn Kramer, MD, FAAN

The chief medical officer at Eisai provided context towards the ongoing initiatives to further the efficacy and safety profile of lecanemab, an FDA-approved treatment for early Alzheimer disease. [WATCH TIME: 3 minutes]

Innovative Phase 2 Proof-of-Concept Trial to Test Effects of Benfotiamine as Alzheimer Treatment

The trial will use phase 2a to determine the optimal dosage while phase 2b will assess efficacy and long-term safety of the optimized dose against a placebo arm.

Alzheimer Agent T3D-959 Demonstrates Disease-Modifying Effects in Phase 2 PIONEER Trial

The drug showed a strong safety profile and met primary endpoints, showing efficacy in slowing clinical and biological decline and supporting further investigation in a phase 2/3 trial.

Exploring Wildfire Smoke Exposure and Risk of Dementia in an Older Patient Population: Joan A. Casey, PhD & Holly Elser, MD, PhD, MPH

A duo of experts talked about the association of long-term exposure to fine particulate matter from wildfires and the increased risk of dementia among older adults. [WATCH TIME: 7 minutes]

Alzheimer Vaccine ALZ-101 Shows Safety, Oligomer-Specific Humoral Immune Response in Early-Stage Trial

The vaccine induced a specific humoral immune response, positively affecting several AD-related biomarkers, and showed potential as a treatment for AD, with further trials planned.

Improving Alzheimer Disease Diagnosis Through Efficient Referrals of Blood Tests: Soeren Mattke, MD, DSc

The director of the Brain Health Observatory at the University of Southern California talked about integrating blood tests into primary care to better triage patients with Alzheimer disease, reduce unnecessary referrals, and shorten appointment wait times. [WATCH TIME: 7 minutes]

Transforming the Landscape of Parkinson Disease Care Through Patient-Centric Focus

Michael Soileau, MD, FAAN, talked about a panel of specialists who discussed the evolution and multidisciplinary treatment of Parkinson disease, emphasizing patient-centered care and advanced therapeutic options.

Episode 120: Improving Gait in Multiple Sclerosis Through the Neural Sleeve

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Douglas Wajda, PhD. [LISTEN TIME: 13 minutes]

Advances in Therapeutic Management for Parkinson Disease and Essential Tremor

Anvi Gadani, MD, assistant clinical professor of medicine at Medstar Georgetown University Hospital, discussed surgical and device-guided therapies for managing advanced Parkinson disease and essential tremor.

NeuroVoices: David Shprecher, DO, MSci, FAAN, on Current and Future Directions in Biomarker Testing for Atypical Parkinsonism

The director of movement disorders at the Banner Sun Health Research Institute talked about recent, promising advancements for diagnosing atypical Parkinsonian disorders and the questions that remain.

Potential of BTK Inhibitors for Primary Progressive Multiple Sclerosis: Patricia K. Coyle, MD

The professor of neurology at Stony Brook Medicine talked about the promising potential in ongoing studies assessing BTK inhibitors as treatment for primary progressive multiple sclerosis. [WATCH TIME: 3 minutes]

Optimizing Localization in Multiple Sclerosis Diagnosis: Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN

The assistant professor at Hunter College talked about the approach of localization to prevent misdiagnoses of multiple sclerosis and ensure patients receive appropriate treatment. [WATCH TIME: 3 minutes]

A Comprehensive Program to Enhance Inpatient Care for Patients With Parkinson Disease

Patricia Clark, CNP, a nurse practitioner at the Cleveland Clinic, talked about a specialized program for hospitalized patients with Parkinson disease that aligns hospital protocols with home medication regimens to improve care.

Streamlining MS Diagnosis and Treatment Through Effective Localization: Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN

The assistant professor at Hunter College talked about how to effectively diagnose and treat multiple sclerosis through localization and active listening of the patient's history and symptoms. [WATCH TIME: 7 minutes]

Promoting Early Rehabilitation and Wellness for Patients With Multiple Sclerosis: Kathy Zackowski, PhD, OTR

The associate vice president of research at National MS Society talked about proactive and early referral to rehabilitation services to effectively manage multiple sclerosis symptoms from the outset. [WATCH TIME: 4 minutes]

Overviewing the XYLO Study and Low-Sodium Oxybate’s Impact on Blood Pressure: Phil Jochelson, MD

The therapeutic head for Clinical Development Neuroscience at Jazz Pharmaceuticals provided clinical insight on a new study evaluating the effect of switching from high- to low-sodium oxybate on blood pressure. [WATCH TIME: 4 minutes]

Future Research Efforts in Aging MS